The board of directors of Shanghai Henlius Biotech, Inc. announced that Mr. Wenjie Zhang (Mr. Zhang) has tendered his resignation as the chief executive officer of the Company (the Chief Executive Officer) with effect from 17 July 2023 due to the adjustment in the focus of work. Mr. Zhang will continue to serve as an executive director and the Chairman of the Company, the chairman of the strategy committee (the Strategy Committee), the chairman of the nomination committee and a member of the environmental, social and governance committee (the Environmental, Social and Governance Committee) under the Board. The Board announced that Mr. Jun Zhu (Mr. Zhu) has been appointed as the Chief Executive Officer with effect from 17 July 2023.

Mr. Zhu, as the Chief Executive Officer, the president and the chief financial officer of the Company, will take a lead role in the Company 's day-to-day management and exercise his functions and powers in accordance with the Articles of Association of Shanghai Henlius Biotech, Inc. (the Articles of Association). Mr. Jun Zhu, aged 45, has joined the Group since December 2020, and currently serves as the Chief Executive Officer, president and chief financial officer of the Company and holds directorship and other positions in certain subsidiaries of the Company. Before joining the Group, Mr. Zhu served as the internal medicine physician in Huashan Hospital affiliated to Fudan University in Shanghai, the project manager and global vice-president of IQVIA Holdings Inc., the general manager in Greater China of Omnicare Clinical Research Inc., the founder and chief executive officer of Shanghai PPC Biopharmaceutical Technology Co.

Ltd. Mr. Zhu obtained a bachelor's degree in clinical medicine from Fudan University in China in July 2001 and an EMBA degree from Cheung Kong Graduate School of Business in China in September 2018.